Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion

Guggenheim's Rating of Bolt Biotherapeutics on 3/8/2021

On March 8, 2021, Guggenheim updated its outlook on Bolt Biotherapeutics (NASDAQ:BOLT) with the action "Initiated Coverage", setting a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Guggenheim

DateCompanyAction
10/26/2026
NetApp, Inc. stock logo
NTAP
NetApp
Initiated Coverage
10/26/2026
Nutanix stock logo
NTNX
Nutanix
Initiated Coverage
10/23/2026
Paylocity Holding Corporation stock logo
PCTY
Paylocity
Boost Price Target
10/23/2026
AppFolio, Inc. stock logo
APPF
AppFolio
Boost Price Target
10/23/2026
ServiceNow, Inc. stock logo
NOW
ServiceNow
Reiterated Rating
10/23/2026
Paycom Software, Inc. stock logo
PAYC
Paycom Software
Boost Price Target
More Ratings From Guggenheim